Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated (Nasdaq: CYTK) is a specialty cardiovascular biopharmaceutical company that regularly issues news about its medicines and programs in cardiac muscle dysfunction. Company updates frequently highlight MYQORZO (aficamten), a cardiac myosin inhibitor that Cytokinetics reports is approved in the United States and China for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, as well as related regulatory developments in other regions.
News for CYTK often covers key regulatory milestones such as positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency, approvals by national regulatory agencies and progress of New Drug Application reviews. Cytokinetics also reports on clinical trial data from studies like SEQUOIA-HCM and MAPLE-HCM, including results presented at major cardiology congresses and publications in peer-reviewed journals.
Investors and observers can find announcements about the company’s broader pipeline, including omecamtiv mecarbil in heart failure with severely reduced ejection fraction, ulacamten in heart failure with preserved ejection fraction and CK-089 in skeletal muscle disorders. Additional news items describe financial results, capital raising activities, inducement equity grants, executive appointments and participation in healthcare and investor conferences.
This CYTK news page aggregates these disclosures so readers can follow developments in Cytokinetics’ cardiovascular programs, regulatory interactions and corporate activities over time.
The FDA has granted Fast Track designation to omecamtiv mecarbil, a cardiac myosin activator from Cytokinetics and Amgen, for treating chronic heart failure with reduced ejection fraction (HFrEF). This designation may speed up the review process for drugs addressing unmet medical needs. The ongoing GALACTIC-HF study, which enrolled 8,256 patients globally, aims to evaluate omecamtiv mecarbil's effectiveness in reducing heart failure events and cardiovascular deaths. Top-line results are expected in Q4 2020.
Cytokinetics (Nasdaq: CYTK) announced its Annual Meeting of Stockholders on May 13, 2020, at 10:30 AM PT in South San Francisco. Due to COVID-19, safety measures including masks and temperature checks will be implemented. Stockholders of record by March 23, 2020, are eligible to vote either in person or via proxy until May 12, 2020, at 11:59 PM ET. A live webcast of the meeting and subsequent CEO presentation will be available on the company's website. Cytokinetics focuses on developing innovative muscle activators and inhibitors for diseases that affect muscle performance.
Cytokinetics, incorporated (NASDAQ: CYTK) reported a net loss of $39.4 million, or $0.66 per share for Q1 2020, compared to a loss of $29.4 million, or $0.54 per share in Q1 2019. Cash, cash equivalents, and investments stand at $237.2 million, providing a runway of over two years based on expected spending of $105-115 million in 2020. The company anticipates top-line results from the GALACTIC-HF trial in Q4 2020 and continues to prioritize clinical programs despite COVID-19 related challenges.